LUVOX (fluvoxamine maleate) by Jazz Pharmaceuticals is neurons. First approved in 2008.
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
LUVOX (fluvoxamine maleate) is an oral selective serotonin reuptake inhibitor (SSRI) approved for psychiatric indications. It works by potently inhibiting the serotonin reuptake transporter on neurons, increasing serotonin availability in the central nervous system. The drug has been marketed since 2008 and is currently approaching loss of exclusivity.
As LOE approaches, the brand team is likely focused on lifecycle extension strategies and managing competitive pressure from SSRI alternatives.
neurons. Fluvoxamine has been shown to be a potent inhibitor of the serotonin reuptake transporter in preclinical studies, both in vitro and in vivo .
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects
A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers
Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.
Worked on LUVOX at Jazz Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on LUVOX at LOE approaching stage offers experience in mature product management, competitive repositioning, and managed care navigation—valuable skills in the generic-dominated psychiatry market. However, limited job openings and stable/declining revenue suggest fewer growth opportunities compared to peak-stage products.